Skip to main content
SpringerLink
Log in

Biological Agents for Chronic Wounds

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Tumor necrosis factor alpha antagonists (e.g. etanercept) are now being extensively evaluated in the setting of chronic wound healing. Preliminary studies and case reports provide evidence of the clinical potential of these compounds in pyoderma gangrenosum, and further investigations are warranted. A clear rationale also exists for further detailed assessments of the potential efficacy of etanercept in patients with venous leg ulcers or hospital-acquired pressure ulcers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26: 1856–61

    Article  PubMed  CAS  Google Scholar 

  2. Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989; 321: 76–9

    Article  PubMed  CAS  Google Scholar 

  3. Tabrizi MN, Chams-Davatchi C, Esmaeeli N, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a doubleblind, randomized, controlled trial. J Eur Acad Dermatol Venereol 2007; 21: 79–84

    Article  PubMed  CAS  Google Scholar 

  4. Ma B, Cheng DS, Xia ZF, et al. Randomized, multicenter, double-blind, and placebo-controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial-thickness burns and skin graft donor site. Wound Repair Regen 2007; 15: 795–9

    Article  PubMed  Google Scholar 

  5. Yao C, Yao P, Wu H, et al. Acceleration of wound healing in traumatic ulcers by absorbable collagen sponge containing recombinant basic fibroblast growth factor. Biomed Mater 2006; 1: 33–7

    Article  PubMed  CAS  Google Scholar 

  6. Groves RW, Schmidt-Lucke JA. Recombinant human GM-CSF in the treatment of poorly healing wounds. Adv Skin Wound Care 2000; 13: 107–12

    PubMed  CAS  Google Scholar 

  7. Gilpin DA, Barrow RE, Rutan RL, et al. Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. Ann Surg 1994; 220: 19–24

    Article  PubMed  CAS  Google Scholar 

  8. Robson MC, Phillips TJ, Falanga V, et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 2001; 9: 347–52

    Article  PubMed  CAS  Google Scholar 

  9. Landi F, Aloe L, Russo A, et al. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med 2003; 139: 635–41

    PubMed  CAS  Google Scholar 

  10. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006; 117 (7 Suppl.): 143S–149S; discussion 150S-151S

    PubMed  CAS  Google Scholar 

  11. Cohen MA, Eaglstein WH. Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds. J Am Acad Dermatol 2001; 45: 857–62

    Article  PubMed  CAS  Google Scholar 

  12. Rees RS, Robson MC, Smiell JM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen 1999; 7: 141–7

    Article  PubMed  CAS  Google Scholar 

  13. Eming SA, Smola H, Krieg T. Treatment of chronic wounds: state of the art and future concepts. Cells Tissues Organs 2002; 172: 105–17

    Article  PubMed  CAS  Google Scholar 

  14. Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care 2004; 17: 24–35

    Article  PubMed  Google Scholar 

  15. Hanft JR, Pollak RA, Barbul A, et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 2008; 17: 30–7

    PubMed  CAS  Google Scholar 

  16. Spear M. Pyoderma gangrenosum: an overview. Plast Surg Nurs 2008; 28: 154–7

    PubMed  Google Scholar 

  17. Wollina U. Pyoderma gangrenosum–a review. Orphanet J Rare Dis 2007; 2: 19

    Article  PubMed  Google Scholar 

  18. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505–9

    Article  PubMed  CAS  Google Scholar 

  19. Charles CA, Leon A, Banta MR, et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007; 46: 1095–9

    Article  PubMed  Google Scholar 

  20. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821–6

    Article  PubMed  CAS  Google Scholar 

  21. Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 2005; 16: 347–9

    Article  PubMed  CAS  Google Scholar 

  22. McGowan JWt, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004; 3: 441–4

    PubMed  Google Scholar 

  23. Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNFalpha drug-Etanercept. J Plast Reconstr Aesthet Surg 2008; 61: 431–3

    Article  PubMed  Google Scholar 

  24. Adisen E, Oztas M, Gurer MA. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy? Dermatology 2008; 216: 163–5

    Article  PubMed  CAS  Google Scholar 

  25. Marzano AV, Tourlaki A, Alessi E, et al. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol 2008; 33: 156–9

    Article  PubMed  CAS  Google Scholar 

  26. Swale VJ, Saha M, Kapur N, et al. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol 2005; 30: 134–6

    Article  PubMed  CAS  Google Scholar 

  27. Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn’s disease: rapid cure with infliximab. Dermatology 2002; 205: 278–80

    Article  PubMed  CAS  Google Scholar 

  28. Juillerat P, Christen-Zach S, Troillet FX, et al. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology 2007; 215: 245–51

    Article  PubMed  Google Scholar 

  29. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002; 37: 1108–10

    Article  PubMed  CAS  Google Scholar 

  30. Valencia IC, Falabella A, Kirsner RS, et al. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol 2001; 44: 401–21; quiz on p. 422-4

    Article  PubMed  CAS  Google Scholar 

  31. de Araujo T, Valencia I, Federman DG, et al. Managing the patient with venous ulcers. Ann Intern Med 2003; 138: 326–34

    PubMed  Google Scholar 

  32. De Araujo TS, Hexsel CL, Kirsner RS. Treatment of venous ulcers. Curr Treat Options Cardiovasc Med 2005; 7: 131–8

    Article  PubMed  Google Scholar 

  33. Sackheim K, De Araujo TS, Kirsner RS. Compression modalities and dressings: their use in venous ulcers. Dermatol Ther 2006; 19: 338–47

    Article  PubMed  Google Scholar 

  34. Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limb compression bandages? Am J Med 2000; 109: 15–9

    Article  PubMed  CAS  Google Scholar 

  35. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen 2000; 8: 13–25

    Article  PubMed  CAS  Google Scholar 

  36. Tian YW, Stacey MC. Cytokines and growth factors in keratinocytes and sweat glands in chronic venous leg ulcers. An immunohistochemical study. Wound Repair Regen 2003; 11: 316–25

    Article  PubMed  Google Scholar 

  37. Wallace HJ, Stacey MC. Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers–correlations to healing status. J Invest Dermatol 1998; 110: 292–6

    Article  PubMed  CAS  Google Scholar 

  38. Cowin AJ, Hatzirodos N, Rigden J, et al. Etanercept decreases tumor necrosis factor-alpha activity in chronicwound fluid. Wound Repair Regen 2006; 14: 421–6

    Article  PubMed  Google Scholar 

  39. Takahashi PY, Ziemele LJ, Jones Jr JP. Wound care for elderly patients: advances and clinical applications for practicing physicians. Mayo Clin Proc 2004; 79: 260–7

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Editorial assistance for the preparation of this manuscript was provided by Stephanie Blick of inScience Communications. This assistance was funded by Pfizer. Dr Kirsner reports no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 N.W. 10th Avenue, RMSB, Room 2023-A, Miami, 33136, Florida, USA

    Robert S. Kirsner

Authors
  1. Robert S. Kirsner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirsner, R.S. Biological Agents for Chronic Wounds. AM J Clin Dermatol 11 (Suppl 1), 23–25 (2010). https://doi.org/10.2165/1153417-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1153417-S0-000000000-00000

Keywords

Search

Navigation